Veronica Asnaghi

Veronica Asnaghi has extensive work experience, beginning with a House Officer role at Clinica Medica in 1997. Veronica then moved to the Schepens Eye Research Institute as a Postdoctoral Fellow in 1999, followed by a Researcher role at the Renal Pathophysiology Laboratory in 2003. In 2002, they were a House Officer at Endocrinology. From 2004 to 2017, they held various roles at Hoffmann-La Roche, including Safety Science Leader, Senior Safety Scientist, Medical Director, Associate Medical Director, Clinical Scientist, and Clinical Science Specialist. In 2017, they became a Clinical Science Leader at NovImmune. Since 2019, they have been at Sobi - Swedish Orphan Biovitrum AB (publ), where they are currently the Vice President, Head of Clinical Science Immunology and Senior Clinical Science Leader. In 2022, they will become the Head of Clinical Science at Topas Therapeutics GmbH.

Veronica Asnaghi obtained their Medical Doctor degree from Università degli Studi di Milano in 1997. In 2003, they completed their specialization in Endocrinology and Metabolic Diseases at the same university.